Table 4. Association of ceDNA with comorbidities.

		crude			adjusted
	n	CR	95% CI	p-value	AR	95% CI	p-value
Severe infection/sepsis	52	1.43	1.19–1.72	< 0.001	1.34	1.11–1.63	0.003
Active cancer	127	1.18	1.04–1.34	0.011	1.09	0.95–1.24	0.234
Arterial hypertension	388	1.06	0.95–1.18	0.274	1.10	0.98–1.23	0.114
Diabetes mellitus	97	1.02	0.89–1.18	0.744	0.98	0.84–1.14	0.785
Chronic lung disease	80	0.97	0.83–1.13	0.678	0.90	0.77–1.06	0.211
Chronic or acute heart failure	78	1.03	0.88–1.20	0.722	1.00	0.85–1.18	0.981
Inflammatory bowel disease	18	1.04	0.77–1.41	0.803	0.96	0.70–1.31	0.788
Acute rheumatic disease	20	0.99	0.74–1.32	0.935	1.02	0.76–1.37	0.886
Major surgery	106	1.16	1.01–1.33	0.036	0.99	0.85–1.17	0.945
Renal failure	35	1.11	0.89–1.39	0.351	1.10	0.87–1.40	0.408

Crude and adjusted robust linear regression of log-transformed ceDNA on comorbidities. Adjustment was done for age, gender, severe infection/sepsis, active cancer, arterial hypertension, diabetes mellitus, chronic lung disease, chronic or acute heart failure, inflammatory bowel disease, acute rheumatic disease, major surgery, renal failure (GFR < 30 ml/min), estrogen therapy, immobilization, history of major bleeding, anemia, concomitant antiplatelet therapy, and anticoagulation prior to index VTE. Coefficients were back-transformed by exponentiation yielding ratios. CR: crude ratio; AR: adjusted ratio.